Files in this item
Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models
Item metadata
dc.contributor.author | Martínez-Pérez, Carlos | |
dc.contributor.author | Ward, Carol | |
dc.contributor.author | Turnbull, Arran K | |
dc.contributor.author | Mullen, Peter | |
dc.contributor.author | Cook, Graham | |
dc.contributor.author | Meehan, James | |
dc.contributor.author | Jarman, Edward J | |
dc.contributor.author | Thomson, Patrick I T | |
dc.contributor.author | Campbell, Colin J | |
dc.contributor.author | McPhail, Donald | |
dc.contributor.author | Harrison, David James | |
dc.contributor.author | Langdon, Simon P | |
dc.date.accessioned | 2016-04-08T09:30:04Z | |
dc.date.available | 2016-04-08T09:30:04Z | |
dc.date.issued | 2016-04-13 | |
dc.identifier | 240105896 | |
dc.identifier | dc825afc-1c5d-43e0-bd63-586d129cbdc6 | |
dc.identifier | 84962068580 | |
dc.identifier | 000374129200008 | |
dc.identifier.citation | Martínez-Pérez , C , Ward , C , Turnbull , A K , Mullen , P , Cook , G , Meehan , J , Jarman , E J , Thomson , P I T , Campbell , C J , McPhail , D , Harrison , D J & Langdon , S P 2016 , ' Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models ' , British Journal of Cancer , vol. 114 , no. 8 , pp. 905-916 . https://doi.org/10.1038/bjc.2016.6 | en |
dc.identifier.issn | 0007-0920 | |
dc.identifier.other | ORCID: /0000-0001-9041-9988/work/64034208 | |
dc.identifier.other | ORCID: /0000-0002-0841-609X/work/157141053 | |
dc.identifier.uri | https://hdl.handle.net/10023/8579 | |
dc.description | We thank SULSA (Scottish Universities Life Science Alliance) for supporting this project through a SULSA BioSkape Industry PhD Studentship and Antoxis Limited for providing additional funding. We also thank the 7th Framework Programme of the European Union (METOXIA project; HEALTH-F2-2009-222741) for support. | en |
dc.description.abstract | Background: The natural polyphenol myricetin induces cell cycle arrest and apoptosis in preclinical cancer models. We hypothesised that myricetin-derived flavonoids with enhanced redox properties, improved cell uptake and mitochondrial targeting might have increased potential as antitumour agents. Methods: We studied the effect of a second-generation flavonoid analogue, Oncamex, in a panel of 7 breast cancer cell lines, applying western blotting, gene expression analysis, fluorescence microscopy, and immunohistochemistry to xenograft tissue to investigate its mechanism of action. Results: Proliferation assays showed that Oncamex: treatment for 8 h reduced cell viability and induced cytotoxicity and apoptosis, concomitant with increased caspase activation. Microarray analysis showed that Oncamex was associated with changes in expression of genes controlling cell cycle and apoptosis . Fluorescence microscopy showed the compound’s mitochondrial targeting and ROS-modulating properties, inducing superoxide production at concentrations associated with anti-proliferative effects. A preliminary in vivo study in mice implanted with the MDA-MB-231 breast cancer xenograft showed that Oncamex inhibited tumour growth, reduced tissue viability and Ki-67 proliferation, with no overall systemic toxicity. Conclusion: Oncamex is a novel flavonoid capable of specific mitochondrial delivery and redox modulation. It has shown antitumour activity in preclinical models of breast cancer, supporting the potential of this prototypic candidate for its continued development as an anticancer agent. | |
dc.format.extent | 2505195 | |
dc.language.iso | eng | |
dc.relation.ispartof | British Journal of Cancer | en |
dc.subject | Novel flavonoids | en |
dc.subject | Preclinical models of cancer | en |
dc.subject | ROS modulation | en |
dc.subject | Breast cancer | en |
dc.subject | Animal models of cancer | en |
dc.subject | Natural products | en |
dc.subject | SAR studies | en |
dc.subject | Xenograft models | en |
dc.subject | Novel antitumour agents | en |
dc.subject | RB Pathology | en |
dc.subject | RC0254 Neoplasms. Tumors. Oncology (including Cancer) | en |
dc.subject | NDAS | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject.lcc | RB | en |
dc.subject.lcc | RC0254 | en |
dc.title | Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models | en |
dc.type | Journal article | en |
dc.contributor.institution | University of St Andrews. School of Medicine | en |
dc.identifier.doi | 10.1038/bjc.2016.6 | |
dc.description.status | Peer reviewed | en |
This item appears in the following Collection(s)
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.